A biopharmaceutical company dedicated to the research and development of novel therapies for the treatment of respiratory diseases.
Enterprise Therapeutics is a biopharmaceutical company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. ET’s scientific strategy is aimed at discovering new disease modifying therapies that target the underlying mechanisms of mucus congestion, which will reduce the frequency of lung infections and improve patient quality of life.
These novel muco-regulatory therapies will be achieved through targeting specific ion channels (TMEM16A and ENaC) to increase the hydration and clearance of mucus. Enterprise has also identified novel targets and compounds that reduce mucus production, an approach that complements mucus hydration therapies. The company currently has 3 small molecule discovery programmes – one already in pre-clinical development and a second scheduled to be IND-ready candidate by late 2018.
In April 2018, ET announced that it had closed an oversubscribed £29 million ($41 million USD) Series B round that will fund the ET’s drug discovery pipeline of muco-regulatory therapies into clinical development, enabling new, disease modifying treatment options for cystic fibrosis, chronic obstructive pulmonary disease and severe asthma.
- CEO John Ford
- Industry Biotech